Registered title, quoted from ClinicalTrials.gov
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Peking Union Medical College Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT03378934, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
platelet count less than 100,000/mm3 or hemoglobin < 10 g/dL.
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT03378934, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion criteria
- Provision of written informed consent.
- Aged 18-70 years, male or female.
- Currently, > 8 but ≤ 40 weeks after index percutaneous coronary intervention (PCI) .
- Receiving dual antiplatelet therapy (DAPT) with aspirin (Bayaspirin TM) 100 mg once daily and clopidogrel (Plavix TM) 75 mg once daily for ≥ 7 days.
- No cardiac ischemic events or bleeding events occurred after the index PCI.
- Cardiac ischemic events include myocardial infarction, coronary revascularization, and definite or probable stent thrombosis;
- Bleeding events include major or minor bleeding according to the Platelet Inhibition and Patient Outcomes (PLATO) definition.
- PRECISE-DAPT score < 25 evaluated after the index PCI and before the index hospital discharge.
- Females who are either post-menopausal > 1 year or surgically sterile.
Exclusion criteria
- Use of berberine within 30 days of screening.
- Use of any fibrinolytic or antithrombotic agents, with the exception of aspirin and clopidogrel, within 30 days of screening.
- Any indications other than coronary artery disease (e.g., atrial fibrillation, prosthetic heart valve, venous thromboembolism, ventricular thrombosis, et al) for fibrinolytic or antithrombotic treatment during the study period.
- Planned use of berberine, as well as any fibrinolytic or antithrombotic agents, with the exception of aspirin (Bayaspirin TM) and clopidogrel (Plavix TM), during the study period.
- Planned use of moderate or strong cytochrome P450 (CYP) 2C19 inhibitors, CYP2C19 substrates with narrow therapeutic index, or strong CYP2C19 inducers during the study period.
- Planned coronary revascularization, including PCI and coronary artery bypass graft (CABG) during the study period.
- Increased bleeding risk, including
- any history of intracranial, intraocular, retroperitoneal, or spinal bleeding;
- recent (within 30 days of screening) gastrointestinal (GI) bleeding;
- recent (within 30 days of screening) major trauma or major surgery;
- planned surgery or other invasive procedure during the study period;
- sustained uncontrolled hypertension (systolic blood pressure [SBP] > 180 mmHg or diastolic blood pressure [DBP] > 100 mmHg);
- history of hemorrhagic disorders, e.g., haemophilia, von Willebrand's disease;
- inability to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during the study period;
- platelet count less than 100,000/mm3 or hemoglobin < 10 g/dL.
- Contraindications for aspirin, clopidogrel, and berberine, e.g., hypersensitivity, active bleeding, bleeding diathesis, coagulation disorders, severe liver or kidney diseases, hemolytic anemia, glucose-6-phosphate dehydrogenase deficiency, et al.
- History of intolerance to aspirin, clopidogrel, and berberine.
- Any condition, which in the opinion of the Investigator, would make it unsuitable for the patient to participate in this study. For example, conditions which may put the patient at risk, e.g., liver or kidney dysfunction, et al; or increase the risk of non-compliance to study protocol or follow-up, e.g., history of drug addiction or alcohol abuse, et al; or influence the result of the study, e.g., active cancer, et al.
- Patients who has previously been randomized in this study.
- Participation in another investigational drug or device study within 30 days of screening.
- Involvement in the planning and conduct of the study (applies to investigators, contract research organization staff, and study site staff, et al).
Quoted from ClinicalTrials.gov, NCT03378934, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT03378934, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.